Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Thorrington, Dominicvan Rossum, Leo
Knol, Mirjam
de Melker, Hester
Rümke, Hans
Hak, Eelko
van Hoek, Albert Jan
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.Published in
Plos One 2018; 13(2):e0192640Publiekssamenvatting
Streptococcus pneumoniae causes morbidity and mortality among all ages in The Netherlands. To reduce this burden, infants in The Netherlands receive the 10-valent pneumococcal conjugated vaccine (PCV10), but older persons are not targeted. We assessed the impact and cost-effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23) or 13-valent PCV (PCV13) among all those aged 60, 65 or 70 and/or in combination with replacing PCV10 with PCV13 in the infant vaccination programme.PMID
29425249ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0192640
Scopus Count
Collections
Related articles
- Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
- Authors: Dirmesropian S, Wood JG, MacIntyre CR, Beutels P, McIntyre P, Menzies R, Reyes JF, Chen C, Newall AT
- Issue date: 2017 Aug 3
- Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.
- Authors: Willem L, Blommaert A, Hanquet G, Thiry N, Bilcke J, Theeten H, Verhaegen J, Goossens H, Beutels P
- Issue date: 2018 May 4
- Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
- Authors: Chen C, Beutels P, Wood J, Menzies R, MacIntyre CR, McIntyre P, Newall AT
- Issue date: 2018 Oct 8
- Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
- Authors: Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR
- Issue date: 2013 Feb
- Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
- Authors: Atwood M, Beausoleil L, Breton MC, Laferriere C, Sato R, Weycker D
- Issue date: 2018 Dec